ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens.

The ALSIUM CONSORTIUM is an international initiative gathering public and private research institutions and aimed at setting up innovative technologies and procedures for tissue engineering. To this end, a perfect multidisciplinary organization must be activated promoting the collaboration among biotechnology, material science, bioinformatics, genetic, biology and clinical medicine investigators. This multidisciplinary approach makes Alsium a platform of excellence to promote the most innovative solutions in regenerative medicine.

AMBiotech S.r.l. was funded in 1999 by research scientists of both governmental and private labs as a spin-off company taking advantage of rich know-how and experiences acquired in the field of plant biotechnologies. Our company operates in the plant biotechnology area, offering both analysis services and technical support. In the last years there’s been a rising interest in exploiting plants as ‘biofactories’ for the production of heterologous proteins of high added value. Indeed plants represent a valid alternative to traditional production systems based on eukaryotic/prokaryotic cell cultures, in terms of product safety/quality and low costs. At present we are involved in research projects in the field of Molecular farming for the large-scale production of Plant-Made Pharmaceuticals (PMPs). (antibodies, vaccines, enzymes, allergens, hormones, antimicrobial peptides etc.)

Competitive Technologies, Inc., established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders.

Delta R&D is a bioengineering research centre with a unique history. It was born out of individual research work begun in 1983 by Giuseppe Marineo, a researcher and bioengineer, who advanced theories to reformulate the concept of disease (and the corresponding treatment) from a biophysical rather than biochemical point of view. The idea was to restructure the known features of both according to the principles of thermodynamics by means of an analysis and the detailed specification of the relations between entropy, disease, repair processes and ageing. In May 1998 Delta R&D was set up, thus marking the beginning of the mature stage of this individual research endeavour. Although the original philosophy was retained, a logistical structure was now available to satisfy the new phases of development and to maintain and expand relations with the international scientific community.

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InSight Biopharmaceuticals Ltd. specializes in the discovery, development, production and commercialization of innovative biopharmaceuticals, diagnostics and biogenerics.

Biogenerics
Since 1995 InSight has been a pioneer in introducing high added value biogenerics to important markets and has established strong alliances for technology transfer and product development. InSight offers a diverse line of biogeneric products, active pharmaceutical ingredients and efficient manufacturing technologies.

Innovative product development
As a major part of its portfolio InSight is developing front-edge biopharmaceuticals and novel drugs. The Company maintains strong R&D programs in cancer, inflammation and additional therapeutic areas. InSight has a rich pipeline of small molecule new chemical entities and novel proteins with promising therapeutic potential, covered by extensive and strong IP.

Diagnostics
Novel products for clinical use in early cancer diagnosis, staging and prognosis, based on InSight's strong IP on Heparanase are being developed.

Istituto Superiore di Sanità: Dept. of Environment and Primary Prevention has recently invented a method to induce or accelerate the proliferation of cells that either are unable to proliferate or have limited replicative potential. The method stems directly from our discovery (J. Cell Biol. 176: 807-818, 2007) that all kinds of non-proliferating cells actively maintain their nonproliferation state by expressing cell cycle inhibitors (CKI). Removal of such inhibitors is sufficient to produce proliferation, even in the absence of growth factors.

LED SpA has a company provided with UNI EN ISO 9001 and UNI EN ISO 13485, whole Quality Certified System that designs and manufactures medical equipment.

Lee's Pharmaceutical Holdings Limited is an integrated research-driven and market-oriented pharmaceutical group. Lee’s aspires to become a successful biopharmaceutical group in Asia providing innovative and high quality pharmaceutical products of value that combat diseases and improve health. Manufacturing and selling activities in China are primarily carried out through Zhaoke, a sino-foreign equity joint venture established in Hefei, Anhui province in 1994. Moreover, the group has obtained license-in drugs and technologies with potential markets from reputable pharmaceutical companies in USA and Europe for both China and Hong Kong markets..

MBS srl (Limited) is a recent spin-off of Roma Tre University, participated by the Roma Tre University itself, the researchers who set-up the method, an Italian small biotech firm and a France seed-capital company. The business idea is to produce and to commercialize an analytical kit patented by University Roma Tre which utilizes disposable, ready-to-use reaction vials for fast microbiological analyses of food and water samples. The analysis is based on the color change of the vial content that is induced by the presence of bacteria. The analyses can be carried out by untrained personnel and everywhere they are necessary, without the need of any other instrumentation but a thermostat provided on request.

Onconova Therapeutics, Inc., a privately held Delaware Corporation, is developing innovative products for combating cancer. We are creating novel Solutions for Oncology by combining conventional pharmaceutical science (a small molecule approach) with the latest genomic and genetic technologies for drug discovery and development.

QuantRx Biomedical is an emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by either medical professionals or consumers, QuantRx is focused on providing more accurate, reliable and faster diagnoses that result in improved patient care. The QuantRx strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of $4 billion worldwide. The Company's technology portfolio, leveraging 15 patents and licenses, includes RapidSense® point-of-care testing products, based on QuantRx core intellectual property related to lateral flow techniques that rapidly provide medical information directly to the healthcare provider or patient. QuantRx affiliate FluoroPharma is developing important molecular imaging agents for positron emission tomography -- PET -- and fluorescence imaging, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment of disease. Initial application is in the treatment of cardiovascular disease. Other QuantRx technology platforms are genome-based diagnostic chips for the laboratory-based diagnostic market and PAD technology for diagnosis and treatment of women's health concerns and other medical needs.

Reimbursement Intelligence provides an array of strategic services to get the managed care knowledge and assessment you need to turn high science into highly successful investments. Our team is comprised of a group of senior managers with more than 20 years of expertise in defining reimbursement strategy and business planning. We are uniquely qualified to provide information and services for emerging medical innovations and the bio-capital resources that fund them. Whether you are an investor needing to understand the reimbursement ramifications surrounding the product you are investing in, or an executive who needs to ensure your managed market success, we can help. Investing in or managing a life science or biotech business is not just about the science, it is also about the business and the impact reimbursement issues can have on commercial success.

Strale Tecnologie e Sistemi Srl is a company headquartered in Rome. Its mission is the design, planning and supply of value added products and services in the ICT sector. The Company, founded in 2006, became operative in September of the same year. It went through the first start-up phase, the most demanding period for a company, as everybody knows. Presently, the market areas to which the company referes to are: Public and private Health; Local and central public administration; Small and Medium companies; Banks and insurance companies. The Company has obtained the ISO 9001:2000 quality certification for design planning, development, support maintenence, installation of data processing products in IT and Telemedicine sector: IT services supply.